Based on these encouraging data and in the light of the problems in directly targeting the c-MYC protooncogene, the use of FASN inhibitors might represent a valid therapeutic approach for HCC, at least in the tumor subset showing activation of c-MYC. Here, FASN is linked to hepatocellular carcinoma.